Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03026036 · ClinicalTrials.gov registry record
Neuroimaging Studies of Reward Processing in Depression
A clinical trial, sponsored by Mclean Hospital.
- Completed
- Registry status
- 123
- Enrollment target
NCT03026036: Completed study, sponsored by Mclean Hospital.
NCT03026036 is a clinical trial that has completed, run by Mclean Hospital. The registered enrollment target is 123 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03026036 has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- 123 participants
- Enrollment target
Study Summary
This study investigates stress-related signaling of glutamate and dopamine within the reward-processing circuit in Major Depressive Disorder (MDD), and whether they can be used to predict depressive symptoms in the future. This will be achieved through various neuroimaging tools (MRS, fMRI, PET), behavioral tasks, and a naturalistic follow-up design.
Primary Outcome
The Probablilistic Reward Task operationalizes positive reinforcement learning
Interventions
- RADIATION PET Scan with Raclopride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2016-04 |
| Est. Completion | 2021-03 |
What the finished NCT03026036 record still lists
NCT03026036 is an observational study that tracks outcomes without assigning an intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which PET Scan with Raclopride is the first listed.
NCT03026036 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03026036 about?
NCT03026036 is a clinical study titled "Neuroimaging Studies of Reward Processing in Depression". This study investigates stress-related signaling of glutamate and dopamine within the reward-processing circuit in Major Depressive Disorder (MDD), and whether they can be used to predict depressive symptoms in the future. This will be achieved through various neuroimaging tools (MRS, fMRI, PET), be...
What is the current status of trial NCT03026036?
This trial is currently completed. The enrollment target is 123 participants. The study started on 2016-04. Estimated completion is 2021-03.
What interventions are being tested in trial NCT03026036?
The interventions under investigation include: PET Scan with Raclopride (RADIATION).
Who is sponsoring clinical trial NCT03026036?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia